Browse by author
Lookup NU author(s): Dr James Wilson, Dr Ashraf Azzabi, Dr Jacqueline Stockley, Professor Naeem Soomro, Garrett Durkan
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2015 Elsevier Inc. Background and objective: Sequential tissue biopsies taken during clinical trials of novel systemic anticancer therapies for advanced prostate cancer (PCa) may aid pharmacodynamic evaluation and biomarker discovery. We conducted a single institution phase-II open-labeled randomized study to assess the safety, tolerability, and early efficacy of docetaxel chemotherapy plus androgen deprivation therapy (ADT) vs. ADT alone for patients with advanced non-castration-resistant PCa with sequential prostatic biopsies. Patients and methods: We randomized 30 patients with newly diagnosed high-grade locally advanced or metastatic (cT3-4/N0-1/M0-1) PCa to receive ADT with (n = 15) or without (n = 15) docetaxel. Transrectal ultrasound-guided prostatic biopsies were taken at randomization and ~22 weeks after treatment initiation. Primary end point: biochemical response rate. Secondary end points: time to progression and tumor profiling. Results: Both treatments appear to be well tolerated, and there was no difference in mean nadir prostate-specific antigen and time to prostate-specific antigen relapse between treatment arms (P>0.05). No adverse effects of pre- and post-treatment prostatic biopsies were observed. The study was neither designed nor sufficiently powered to demonstrate statistically significant differences in oncological outcomes or safety profiles between the 2 treatment arms. Conclusions: Despite the lack of statistical power, our study suggests that docetaxel and ADT in combination may be well tolerated with apparently similar short-term efficacy compared with ADT alone for high-grade locally advanced or metastatic non-castration-resistant PCa, Sequential prostatic biopsies may provide tissue for tumor profiling to yield mechanistic or prognostic insights relating to novel systemic anticancer therapies.
Author(s): Rajan P, Frew JA, Wilson JM, Azzabi AST, McMenemin RM, Stockley J, Soomro NA, Durkan G, Pedley ID, Leung HY
Publication type: Article
Publication status: Published
Journal: Urologic Oncology: Seminars and Original Investigations
Year: 2015
Volume: 33
Issue: 8
Pages: 337.e1-337.e6
Online publication date: 16/06/2015
Acceptance date: 11/05/2015
ISSN (print): 1078-1439
ISSN (electronic): 1873-2496
Publisher: Elsevier Inc.
URL: http://doi.org/10.1016/j.urolonc.2015.05.012
DOI: 10.1016/j.urolonc.2015.05.012
Altmetrics provided by Altmetric